Literature DB >> 2544155

Augmented pituitary corticotropin response to a threshold dosage of human corticotropin-releasing hormone in depressives pretreated with metyrapone.

J Lisansky1, G T Peake, R J Strassman, C Qualls, A W Meikle, S C Risch, G A Fava, M Zownir-Brazis, P Hochla, D Britton.   

Abstract

We studied pituitary corticotropin response to exogenous corticotropin-releasing hormone infusion and attempted to control for the confounding effect of variable serum cortisol levels between depressed and control subjects. If metyrapone was given during the time of day when hypothalamic pituitary adrenal activity was otherwise low, the relative increase in the corticotropin concentration was small. Pituitary response to exogenous corticotropin-releasing hormone can be defined under conditions in which the amount of glucocorticoid-mediated negative feedback present at the level of the pituitary gland is equal in all subjects. When the ambient cortisol level was equalized (and suppressed) in all subjects at the time of study with a threshold dosage of corticotropin-releasing hormone, we found an augmented response to corticotropin-releasing hormone in depressives. This raises the possibility that either increased pituitary sensitivity to corticotropin-releasing hormone or an increased intracellular pool of corticotropin is available for release in subjects with major depressive illness.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2544155     DOI: 10.1001/archpsyc.1989.01810070067011

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  8 in total

Review 1.  Magnetic resonance in patients with affective illness.

Authors:  W M McDonald; K R Krishnan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1992       Impact factor: 5.270

2.  Sex differences in neurosteroid and hormonal responses to metyrapone in posttraumatic stress disorder.

Authors:  Sabra S Inslicht; Anne Richards; Erin Madden; Madhu N Rao; Aoife O'Donovan; Lisa S Talbot; Evelyn Rucker; Thomas J Metzler; Richard L Hauger; Thomas C Neylan
Journal:  Psychopharmacology (Berl)       Date:  2014-06-21       Impact factor: 4.530

3.  Pathophysiology of hypercortisolism in depression: pituitary and adrenal responses to low glucocorticoid feedback.

Authors:  B J Carroll; A Iranmanesh; D M Keenan; F Cassidy; W H Wilson; J D Veldhuis
Journal:  Acta Psychiatr Scand       Date:  2011-12-30       Impact factor: 6.392

Review 4.  The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.

Authors:  Ian M Bird; David H Abbott
Journal:  J Steroid Biochem Mol Biol       Date:  2016-05-03       Impact factor: 4.292

5.  Antiglucocorticoids as Treatments for Depression : Rationale for Use and Therapeutic Potential.

Authors:  L H Price; R T Malison; C J McDougle; G H Pelton
Journal:  CNS Drugs       Date:  1996-05       Impact factor: 5.749

Review 6.  Hypothesis: cytokines may be activated to cause depressive illness and chronic fatigue syndrome.

Authors:  E Ur; P D White; A Grossman
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1992       Impact factor: 5.270

7.  Regulation of corticosteroid receptor gene expression in depression and antidepressant action.

Authors:  N Barden
Journal:  J Psychiatry Neurosci       Date:  1999-01       Impact factor: 6.186

Review 8.  Implication of the hypothalamic-pituitary-adrenal axis in the physiopathology of depression.

Authors:  Nicholas Barden
Journal:  J Psychiatry Neurosci       Date:  2004-05       Impact factor: 6.186

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.